Krista L Lanctôt1, Roberta W Scherer2, Abby Li3, Danielle Vieira3, Hamadou Coulibaly2, Paul B Rosenberg4, Nathan Herrmann3, Alan J Lerner5, Prasad R Padala6, Olga Brawman-Mintzer7, Chris H van Dyck8, Anton P Porsteinsson9, Suzanne Craft10, Allan Levey11, William J Burke12, Jacobo E Mintzer7. 1. Sunnybrook Research Institute, Toronto, ON, Canada. Electronic address: krista.lanctot@sunnybrook.ca. 2. Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD. 3. Sunnybrook Research Institute, Toronto, ON, Canada. 4. Johns Hopkins University School of Medicine, Baltimore, MD. 5. University Hospital - Case Western Reserve University, Cleveland, OH. 6. University of Arkansas for Medical Science, Central Arkansas Veterans Healthcare System, Little Rock, AR. 7. Medical University of South Carolina and Ralph H. Johnson Veterans Administration Medical Center, Charleston, SC. 8. Yale University, New Haven, CT. 9. University of Rochester, Rochester, NY. 10. Wake Forest University School of Medicine, Winston-Salem, NC. 11. Emory University, Atlanta, GA. 12. Banner Alzheimer's Institute, Phoenix, AZ.
Abstract
BACKGROUND: Diagnostic criteria for apathy have been published but have yet to be evaluated in the context of clinical trials. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) operationalized the diagnostic criteria for apathy (DCA) into a clinician-rated questionnaire informed by interviews with the patient and caregiver. OBJECTIVE: The goal of the present study was to compare the classification of apathy using the DCA with that using the Neuropsychiatric Inventory-apathy (NPI-apathy) subscale in ADMET 2. Comparisons between NPI-Apathy and Dementia Apathy Interview Rating (DAIR) scale, and DCA and DAIR were also explored. METHODS: ADMET 2 is a randomized, double-blind, placebo-controlled phase III trial examining the effects of 20 mg/day methylphenidate on symptoms of apathy over 6 months in patients with mild to moderate Alzheimer's disease (AD). Participants scoring at least 4 on the NPI-Apathy were recruited. This analysis focuses on cross-sectional correlations between baseline apathy scale scores using cross-tabulation. RESULTS: Of 180 participants, the median age was 76.5 years and they were predominantly white (92.8%) and male (66.1%). The mean (±standard deviation) scores were 7.7 ± 2.4 on the NPI-apathy, and 1.9 ± 0.5 on the DAIR. Of those with NPI-defined apathy, 169 (93.9%, 95% confidence interval [CI] 89.3%-96.9%) met DCA diagnostic criteria. The DCA and DAIR overlapped on apathy diagnosis for 169 participants (93.9%, 95% CI 89.3%-96.9%). CONCLUSION: The measurements used for the assessment of apathy in patients with AD had a high degree of overlap with the DCA. The NPI-apathy cut-off used to determine apathy in ADMET 2 selects those likely to meet DCA criteria.
BACKGROUND: Diagnostic criteria for apathy have been published but have yet to be evaluated in the context of clinical trials. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) operationalized the diagnostic criteria for apathy (DCA) into a clinician-rated questionnaire informed by interviews with the patient and caregiver. OBJECTIVE: The goal of the present study was to compare the classification of apathy using the DCA with that using the Neuropsychiatric Inventory-apathy (NPI-apathy) subscale in ADMET 2. Comparisons between NPI-Apathy and Dementia Apathy Interview Rating (DAIR) scale, and DCA and DAIR were also explored. METHODS: ADMET 2 is a randomized, double-blind, placebo-controlled phase III trial examining the effects of 20 mg/day methylphenidate on symptoms of apathy over 6 months in patients with mild to moderate Alzheimer's disease (AD). Participants scoring at least 4 on the NPI-Apathy were recruited. This analysis focuses on cross-sectional correlations between baseline apathy scale scores using cross-tabulation. RESULTS: Of 180 participants, the median age was 76.5 years and they were predominantly white (92.8%) and male (66.1%). The mean (±standard deviation) scores were 7.7 ± 2.4 on the NPI-apathy, and 1.9 ± 0.5 on the DAIR. Of those with NPI-defined apathy, 169 (93.9%, 95% confidence interval [CI] 89.3%-96.9%) met DCA diagnostic criteria. The DCA and DAIR overlapped on apathy diagnosis for 169 participants (93.9%, 95% CI 89.3%-96.9%). CONCLUSION: The measurements used for the assessment of apathy in patients with AD had a high degree of overlap with the DCA. The NPI-apathy cut-off used to determine apathy in ADMET 2 selects those likely to meet DCA criteria.
Authors: Dana Mohammad; Courtney Ellis; Allison Rau; Paul B Rosenberg; Jacobo Mintzer; Myuri Ruthirakuhan; Nathan Herrmann; Krista L Lanctôt Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Barbara K Martin; Constantine E Frangakis; Paul B Rosenberg; Jacobo E Mintzer; Ira R Katz; Anton P Porsteinsson; Lon S Schneider; Peter V Rabins; Cynthia A Munro; Curtis L Meinert; George Niederehe; Constantine G Lyketsos Journal: Am J Geriatr Psychiatry Date: 2006-11 Impact factor: 4.105
Authors: Jeffrey Cummings; Joseph H Friedman; George Garibaldi; Martin Jones; Wayne Macfadden; Laura Marsh; Philippe H Robert Journal: J Geriatr Psychiatry Neurol Date: 2015-03-24 Impact factor: 2.680
Authors: E Mulin; E Leone; K Dujardin; M Delliaux; A Leentjens; F Nobili; B Dessi; O Tible; L Agüera-Ortiz; R S Osorio; J Yessavage; D Dachevsky; F R J Verhey; Alfonso J Cruz Jentoft; O Blanc; P M Llorca; P H Robert Journal: Int J Geriatr Psychiatry Date: 2011-02 Impact factor: 3.485
Authors: P Robert; C U Onyike; A F G Leentjens; K Dujardin; P Aalten; S Starkstein; F R J Verhey; J Yessavage; J P Clement; D Drapier; F Bayle; M Benoit; P Boyer; P M Lorca; F Thibaut; S Gauthier; G Grossberg; B Vellas; J Byrne Journal: Eur Psychiatry Date: 2009-02-07 Impact factor: 5.361
Authors: Prasad R Padala; Eugenia M Boozer; Shelly Y Lensing; Christopher M Parkes; Cassandra R Hunter; Richard A Dennis; Ricardo Caceda; Kalpana P Padala Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472